Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Capricor Therap (CAPR)

Capricor Therap (CAPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,215
  • Shares Outstanding, K 24,324
  • Annual Sales, $ 240 K
  • Annual Income, $ -20,020 K
  • 60-Month Beta 5.35
  • Price/Sales 338.55
  • Price/Cash Flow N/A
  • Price/Book 3.37
Trade CAPR with:

Options Overview Details

View History
  • Implied Volatility 143.44% ( -12.63%)
  • Historical Volatility 69.07%
  • IV Percentile 73%
  • IV Rank 9.51%
  • IV High 560.53% on 05/11/22
  • IV Low 99.58% on 09/02/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 101
  • Volume Avg (30-Day) 177
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 14,369
  • Open Int (30-Day) 17,095

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.25
  • Number of Estimates 1
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.81 +20.24%
on 05/12/22
3.67 -7.93%
on 05/05/22
+0.21 (+6.59%)
since 04/26/22
3-Month
2.81 +20.24%
on 05/12/22
5.80 -41.74%
on 03/25/22
-1.03 (-23.38%)
since 02/25/22
52-Week
2.56 +31.98%
on 01/24/22
6.22 -45.71%
on 06/22/21
-0.29 (-7.93%)
since 05/26/21

Most Recent Stories

More News
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative...

CAPR : 3.47 (+2.66%)
Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States- ...

CAPR : 3.47 (+2.66%)
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10

Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET...

CAPR : 3.47 (+2.66%)
Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit

SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative...

CAPR : 3.47 (+2.66%)
Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients

-Primary Objective of Study Met: CAP-1002 was Safe and Well Tolerated- SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...

CAPR : 3.47 (+2.66%)
The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy

-One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in...

CAPR : 3.47 (+2.66%)
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

CAP-1002 Cell Therapy Programs -Pivotal Phase 3, HOPE-3 Trial Initiation Underway- -Entered Exclusive Partnership with Nippon Shinyaku for...

CAPR : 3.47 (+2.66%)
Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10

Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET...

CAPR : 3.47 (+2.66%)
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.

-Partnership Leverages Nippon Shinyaku’s Deep Experience in Drug Development for Rare Diseases and its Commercial DMD Franchise in the U.S.- -Capricor to...

CAPR : 3.47 (+2.66%)
Forget Bargains, Play 5 Stocks With Rising P/E Instead

Forget undervalued stocks, there is room for upside even in stocks with rising P/E.

SIRI : 6.30 (+1.61%)
STKL : 7.56 (+3.56%)
SAM : 344.10 (+3.21%)
CAPR : 3.47 (+2.66%)
NDRA : 0.2165 (+3.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 3.64
2nd Resistance Point 3.58
1st Resistance Point 3.48
Last Price 3.47
1st Support Level 3.32
2nd Support Level 3.26
3rd Support Level 3.16

See More

52-Week High 6.22
Fibonacci 61.8% 4.82
Fibonacci 50% 4.39
Fibonacci 38.2% 3.96
Last Price 3.47
52-Week Low 2.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar